MACK: Science Signaling publication shows promise of new drug for breast cancer
Merrimack Network biology work published in Science Signaling maps out positive outcome for bispecific antibody in development. "ERBB2-amplified breast cancer cells stimulated with the ErbB3 ligand heregulin were resistant to growth arrest induced by inhibitors of AKT and MEK or coapplication of two inhibitors of the receptor ErbB2 [Herceptin (trastuzumab) and Tykerb (lapatinib)]. We used model simulations to predict the response of ErbB2-positive breast cancer xenografts to combination therapies and verified these predictions in mice. Treatment with trastuzumab, lapatinib, and the ErbB3 inhibitor MM-111 was more effective in inhibiting tumor growth than the combination of AKT and MEK inhibitors and even induced tumor regression, indicating that targeting both ErbB3 and ErbB2 may be an improved therapeutic approach for ErbB2-positive breast cancer patients."
Phase I is compelted and successful adn MM-111 advanced to phase II earlier this year and MM-111 is actively recruiting in 2 phase II studies in patients With HER2 Positive cancer. MM-111 is designed as a trojan horse that targets HER-2 positive cancer cells and facilitates HER-3 signalling inhibition blocking promotion of the development, growth and progression of cancer. The network biology research behind the developement of this drug Proof of concept is worthy of consideration for a Nobel Prize. Read the paper. This technology is and will be moreso goign forward the future of drug discovery. HER-3 drugs will work across a broad range of HER-2 positive cancers and will be given in combination with several different blockbuster cancer antibody and chemotherapies already on the market making MM-111 a portential mega-blockbuster cancer treatment that will extend the lives of many patients.